Prandilin(R)25

Products

Information

Prandilin(R)25 is a premix insulin lispro suspension developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2014. As a fast-acting biosimilar insulin, Prandilin(R)25 is able to rapidly and stablely control human blood sugar 15-20mins after injection before a meal for the treatment of diabetes.
Distribution Areas
AfricaMiddle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
All categories
Biopharmaceutical ProductsFinished Dosage FormsBiosimilarsProducts
Main Categories
Biopharmaceutical ProductsFinished Dosage Forms
Gan & Lee PharmaceuticalsFounded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug product...

Log in

See all the content and easy-to-use features by logging in or registering!